Poly(ADPR)polymerase-1 signalling of the DNA damage induced by DNA topoisomerase I poison in D54(p53wt) and U251(p53mut) glioblastoma cell lines.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Pharmacological Research

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.PHRS.2006.10.005PMID 17127074
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Poly(ADP-RIBOSE) polymerase-1 (Parp-1) antagonizes topoisomerase I-dependent recombination stimulation by P53

  2006cited by this paper
• The Novel Poly(ADP-Ribose) Polymerase Inhibitor, AG14361, Sensitizes Cells to Topoisomerase I Poisons by Increasing the Persistence of DNA Strand Breaks

  2005cited by this paper
• Topotecan-triggered degradation of topoisomerase I is p53-dependent and impacts cell survival.

  2005cited by this paper
• Chemopotentiation by PARP inhibitors in cancer therapy.

  2005cited by this paper
• Poly(ADP-ribose) polymerase-1 could facilitate the religation of topoisomerase I-linked DNA inhibited by camptothecin.

  2005cited by this paper
• p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition

  2004cited by this paper
• Poly(ADP-ribosylation) and apoptosis

  2004cited by this paper
• Dual role for poly(ADP-ribose)polymerase-1 and -2 and poly(ADP-ribose)glycohydrolase as DNA-repair and pro-apoptotic factors in rat germinal cells exposed to nitric oxide donors.

  2004cited by this paper
• Poly(ADP-ribose) Reactivates Stalled DNA Topoisomerase I and Induces DNA Strand Break Resealing*

  2004cited by this paper
• Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts

  2004cited by this paper
• Poly(ADP‐ribosyl)ation inhibitors: Promising drug candidates for a wide variety of pathophysiologic conditions

  2004cited by this paper
• Inactivation of wild-type p53 protein function by reactive oxygen and nitrogen species in malignant glioma cells.

  2003cited by this paper
• Central and carboxy‐terminal regions of human p53 protein are essential for interaction and complex formation with PARP‐1

  2003cited by this paper
• Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.

  2002cited by this paper
• Cellular roles of DNA topoisomerases: a molecular perspective

  2002cited by this paper
• Poly(ADP‐ribose) polymerase inhibitor increases growth inhibition and reduces G2/M cell accumulation induced by temozolomide in malignant glioma cells

  2002cited by this paper
• Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.

  2002cited by this paper
• Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro

  2001cited by this paper
• Regulation of p53 Sequence-specific DNA-binding by Covalent Poly(ADP-ribosyl)ation*

  2001cited by this paper
• Physiology and pathophysiology of poly(ADP‐ribosyl)ation *

  2001cited by this paper
• p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells.

  2001cited by this paper
• Cell cycle-mediated drug resistance: an emerging concept in cancer therapy.

  2001cited by this paper
• Expression of poly(ADP‐ribose) polymerase and distribution of poly(ADP‐ribosyl)ation in glioblastoma and in a glioma multicellular tumour spheroid model

  2000cited by this paper
• From DNA damage and stress signalling to cell death : poly-ADP-ribosylation reactions

  2000cited by this paper
• DNA Excision Repair and DNA Damage-Induced Apoptosis Are Linked to Poly(ADP-Ribosyl)ation but Have Different Requirements for p53

  2000cited by this paper
• Poly(ADP-ribose) Binds to Specific Domains in DNA Damage Checkpoint Proteins*

  2000cited by this paper
• Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.

  2000cited by this paper
• Poly(ADP-ribosylation) and apoptosis.

  1999cited by this paper
• The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53.

  1999cited by this paper
• Prolongation of the p53 response to DNA strand breaks in cells depleted of PARP by antisense RNA expression.

  1998cited by this paper
• Poly(ADP-ribose) Binds to Specific Domains of p53 and Alters Its DNA Binding Functions*

  1998cited by this paper
• Defective induction but normal activation and function of p53 in mouse cells lacking poly-ADP-ribose polymerase

  1997cited by this paper
• p53, the Cellular Gatekeeper Review for Growth and Division

  1997cited by this paper
• Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates.

  1993cited by this paper
• Poly(ADP-ribosylation) of DNA topoisomerase I from calf thymus.

  1984cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper

• Poly(ADP-ribose) polymerase (PARP) inhibitors in cardiovascular, and cerebrovascular diseases: mechanisms, current trends and challenge for clinical translation.

  2026cites this paper
• 4-Furanylvinylquinoline derivative as a new scaffold for the design of oxidative stress initiator and glucose transporter inhibitor drugs

  2024cites this paper
• TCH1036, a indeno[1,2-c]quinoline derivative, potentially inhibited the growth of human brain malignant glioma (GBM) 8401 cells via suppression of the expression of Suv39h1 and PARP.

  2016cites this paper
• Effect of p53 activity on the sensitivity of human glioblastoma cells to PARP‐1 inhibitor in combination with topoisomerase i inhibitor or radiation

  2014cites this paper
• Mecanismos de reparo de DNA envolvidos com lesões induzidas por agente alquilante (Nimustina) em células humanas e sua associação com a resistência de gliomas.

  2014cites this paper
• Diaphanous-Related Formin Hyperactivation is Superior to its Inactivation as an Anti- Invasive Strategy for Glioblastoma

  2014cites this paper
• Involvement of Poly(ADP-Ribose) polymerase inhibitors as adiuvants of Topoisomerase 1 poisons in the p53/p63-dependent threshold mechanism of the cell fate decision between growth arrest and apoptosis.

  2014cites this paper
• p63 involvement in poly(ADP-ribose) polymerase 1 signaling of topoisomerase I-dependent DNA damage in carcinoma cells.

  2013cites this paper
• Bioinformatics analysis reveals potential candidate drugs for different subtypes of glioma

  2013cites this paper
• Therapeutic intervention by the simultaneous inhibition of DNA repair and type I or type II DNA topoisomerases: one strategy, many outcomes.

  2012cites this paper
• Novel Therapies in Glioblastoma

  2012cites this paper
• Targeted therapy for brain tumours: role of PARP inhibitors.

  2012cites this paper
• Investigation of the role of poly(ADP-ribose)polymerase inhibition in topoisomerase I poison-induced cytotoxicity

  2012cites this paper
• Poly(ADP-ribose) polymerase signaling of topoisomerase 1-dependent DNA damage in carcinoma cells.

  2011cites this paper
• UNIVERSITA' DI NAPOLI "FEDERICO II" DOTTORATO DI RICERCA BIOCHIMICA E BIOLOGIA MOLECOLARE E CELLULARE XXIII CICLO

  2011cites this paper
• Poly(ADP-Ribose) Polymerase (PARP) signaling of DNA damage induced by Topoisomerase 1 (TOP1) inhibition

  2010cites this paper
• Anti-tumor activity of emodin against human chronic myelocytic leukemia K562 cell lines in vitro and in vivo.

  2010cites this paper
• Predictive Factors of Complete Response to Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer

  2010cites this paper
• Antitumor activities and pharmacokinetics of silatecans DB-67 and DB-91.

  2010cites this paper
• Increased cytotoxicity of an unusual DNA topoisomerase II inhibitor compound C-1305 toward HeLa cells with downregulated PARP-1 activity results from re-activation of the p53 pathway and modulation of mitotic checkpoints.

  2010cites this paper
• Low-dose radiation induces adaptive response in normal cells, but not in tumor cells: in vitro and in vivo studies.

  2008cites this paper
• ATP Modulates Poly(ADP-Ribose) Polymerase-1-Facilitated Topoisomerase I-Linked DNA Religation in the Presence of Camptothecin

  2008cites this paper
• Poly(ADPR)polymerase inhibition and apoptosis induction in cDDP-treated human carcinoma cell lines.

  2008cites this paper
• Targeting topoisomerase I: molecular mechanisms and cellular determinants of response to topoisomerase I inhibitors

  2008cites this paper
• Targeting topoisomerase I: molecular mechanisms and cellular determinants of response to topoisomerase I inhibitors.

  2008cites this paper